Renaissance Investment Group LLC Trims Stake in Zoetis Inc. $ZTS

Renaissance Investment Group LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 67.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,535 shares of the company’s stock after selling 37,867 shares during the quarter. Renaissance Investment Group LLC’s holdings in Zoetis were worth $2,332,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC boosted its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in Zoetis in the 4th quarter valued at approximately $38,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. UBS Group set a $136.00 target price on Zoetis in a research note on Thursday, January 29th. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Stock Down 1.1%

Zoetis stock opened at $116.03 on Friday. The stock has a market cap of $48.98 billion, a PE ratio of 19.27, a P/E/G ratio of 1.79 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock’s fifty day moving average is $124.58 and its two-hundred day moving average is $130.88. Zoetis Inc. has a 1-year low of $114.47 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the prior year, the business posted $1.40 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.